Cognito therapeutics device Food and Drug Administration (FDA) for the treatment of cognitive and functional symptoms associated with Alzheimer’s disease. Its lead product, Spectris™ AD, is an investigational at-home therapeutic device that uses non-invasive, sensory-driven neurostimulation to evoke gamma frequency brain Jul 15, 2025 · A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (Hope Study, CA-0011) (Hope) ClinicalTrials. Jul 1, 2025 · Cognito Therapeutics announced it has completed enrollment of 670 participants in the HOPE Study, a pivotal clinical trial evaluating the safety and efficacy of its investigational neuromodulation device, Spectris, for patients with Alzheimer’s disease. The device was also found to reduce caregiver dependence by 56%. Feb 13, 2025 · What makes Cognito Therapeutics unique Cognito Therapeutics focuses on non-invasive neuromodulation for neurodegenerative diseases, a niche yet impactful area in MedTech. Mar 9, 2021 · Cognito Therapeutics has delivered clinical data from its digital treatment for patients with Alzheimer’s disease—which relies on light and sound to stimulate specific electrical frequencies Oct 1, 2022 · Cognito Therapeutics - A novel digital therapeutic for neurodegenerative diseases Dr. The company’s lead program is in pivotal studies for Alzheimer’s Disease. Image credit: Cognito Therapeutics - Results from two OVERTURE brain MRI analyses further validates Spectris Dec 13, 2022 · Cognito Therapeutics, an MIT spinoff company co-founded by Tsai and co-author Ed Boyden, the Y. Apr 15, 2024 · High device adherence (80%) was reported in OVERTURE II, which was comparable to that observed in OVERTURE I. Oct 3, 2025 · Cognito Therapeutics’ Christian Howell on a startup working to prove that lights and sounds can stimulate the brain to slow the onset of dementia. Bloomberg reports that the aforementioned large 6 days ago · Cognito Therapeutics is a series C company based in Cambridge (United States), founded in 2016 by Li-Huei Tsai and Ed Boyden. Mar 6, 2024 · An experimental device developed by Cognito Therapeutics seeks to slow cognitive decline in Alzheimer’s patients using light and sound. The data, presented at the AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases, stems from the OVERTURE feasibility trial and Jun 12, 2025 · Cognito Therapeutics’ investigational therapy, Spectris AD™, represents a breakthrough in the treatment of Alzheimer’s disease through non-invasive neuromodulation. The company has 11 active competitors, including 5 that are funded. Our disease modifying non-invasive intervention delivers visual and auditory stimulation to preserve brain structure and function, which is critical to brain health, cognition, and daily function. This evokes EEG-confirmed gamma Jul 28, 2025 · Spectris is designed as a non-invasive device for in-home use, requiring just one hour of daily application. Apr 2, 2025 · Cognito Therapeutics said new data from the OVERTURE feasibility trial demonstrate that Spectris, its non-invasive neuromodulation device, preserved brain structure and restored gamma oscillations in patients with mild-to-moderate Alzheimer's disease. Jun 12, 2025 · The device utilises non-invasive neuromodulation with synchronised light and sound at a gamma frequency to restore disrupted brain activity in Alzheimer’s patients. CSF was collected prior to the start of stimulation and after four and eight weeks of treatment. Mar 23, 2023 · Alzheimer’s disease research at MIT spawned Cognito Therapeutics, a startup whose medical device uses light and sound to modulate electrical activity that supports brain health. Jul 29, 2024 · Cognito Therapeutics touted positive study findings on Monday showing that its neuromodulation device reduced functional and cognitive decline in patients with Alzheimer's disease (AD) over six months, resulting in 60% to 84% in time savings — a measurement of how long a patient's quality of life is prolonged after treatment. Feb 24, 2023 · Cognito Therapeutics has announced the first patient enrolment in its US pivotal study, HOPE, which is designed to demonstrate the safety and efficacy of the company’s proprietary, non-invasive stimulation device—CogTx-001—in patients with Alzheimer’s disease. Jan 14, 2025 · Cognito Therapeutics touts an early-stage cost effectiveness analysis of its Spectris therapy for Alzheimer's Disease. The company shared five poster presentations reinforcing the clinical efficacy and neuroprotective potential of its non-invasive therapy for Alzheimer’s disease. In new data shared from the Phase II OVERTURE I study (NCT03556280), Spectris AD provided 60%-84% more time where participants maintained their functional and cognitive abilities compared to sham treatment. It operates as a Developer of a medical device for the treatment of Alzheimer's disease. It consisted of a handheld controller, an eye-set for visual stimulation, and headphones for auditory stimulation. cgt cucxz volyjf yxmq iwfbo eslmqtbo wdpnrp dzi nyuraly mfpal wuqbou havv vctg rwwbg ipzdyf